Liquid Biopsies and Minimally-Invasive Diagnostics 2016

in Conferences July 1, 2016

Overview

The 3^rd Annual Liquid Biopsies and Minimally-Invasive Diagnostics 2016 Conference brings together academic researchers, industry researchers, as well as biotechnology and pharmaceutical companies to explore the expanding and evolving field whereby Circulating Biomarkers of various classes are being evaluated for their potential to be developed into diagnostics for cancer as well as other disease classes.

Download Links

Liquid Biopsy Slide Deck

Exosomes Market Dynamics

This Liquid Biopsies Conference focuses primarily on biofluid-based molecular biomarkers, such as circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs), and protein-based circulating biomarkers. There is much interest in the potential of ctDNA for developing biological fluid-based biopsies (such as using plasma, urine, or other biofluids) and the presenters in this track bring together the most up-to-date information and current state-of-the-field.

The conference further explores the potential of various minimally-invasive circulating biomarker classes, such as circulating-free DNA (cfDNA), CTCs, and Extracellular Vesicles (EVs), for development of novel diagnostics for patient monitoring and precision/targeted medicine.

Authors of best abstracts would be offered with the opportunity to publish their full articles in “Special Issue on Liquid Biopsy” of Cancer Translational Medicine Journal.

Call for Posters

You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!

Poster Submission Deadline: 16 September 2016

Agenda Topics

Circulating Tumor Cells (CTCs): Potential for Development of Liquid Biopsies
Circulating Tumor DNA (ctDNA): Potential for Development of Liquid Biopsies
Extracellular Nucleic Acids in the Circulation: Circulating Free DNA, Extracellular RNA and Circulating microRNA/Long Non-Coding RNA
Extracellular Vesicles (EVs): Potential for Development of Liquid Biopsies
US vs. EU vs. Asia/Pacific Regulatory Landscape for Novel Minimally-Invasive Diagnostics

Sponsorship and Exhibition Opportunities

Jeff Fan, Exhibition Manager
jeff@selectbioconferences.com
+1-510-857-4865

Confirmed Speakers to date

Lyle Arnold, Chief Scientific Officer, Biocept
Iwijn De Vlaminck, Robert N. Noyce Assistant Professor in Life Science and Technology Meinig School of Biomedical Engineering, Cornell University
Muller Fabbri, Assistant Professor, University of Southern California
Audrey Goddard, Vice President, Genomic Sciences, Genomic Health, Inc.
Priya Gogoi, Vice President, Strategy and Research, Celsee Diagnostics
Karl Hecker, Vice President of Product Development, Rubicon Genomics, Inc.
James Joyce, Chairman & CEO, Aethlon Medical, Inc.
Hamid Khoja, Principal Scientist, Covaris, Inc.
Louise Laurent, Associate Professor, University of California-San Diego
Ian Papautsky, Professor, University of Cincinnati
Shivani Sharma, Associate Director, California NanoSystems Institute, UCLA
Kendall Van Keuren-Jensen, Associate Professor, Translational Genomics Research Institute
Lingzhi Wang, Senior Research Scientist, Ctr. for Translational Medicine, Adjunct Professor, National University of Singapore